PharmaResearch Co Ltd
KOSDAQ:214450
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R Stahl AG
XETRA:RSL2
|
DE |
PharmaResearch Co Ltd
Total Current Assets
PharmaResearch Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Current Assets
₩759.5B
|
CAGR 3-Years
45%
|
CAGR 5-Years
43%
|
CAGR 10-Years
19%
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Assets
₩6.2T
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Current Assets
₩56.5B
|
CAGR 3-Years
45%
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Assets
₩480.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
34%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Assets
₩176.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Current Assets
₩39.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Total Current Assets?
Total Current Assets
759.5B
KRW
Based on the financial report for Dec 31, 2025, PharmaResearch Co Ltd's Total Current Assets amounts to 759.5B KRW.
What is PharmaResearch Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
19%
Over the last year, the Total Current Assets growth was 37%. The average annual Total Current Assets growth rates for PharmaResearch Co Ltd have been 45% over the past three years , 43% over the past five years , and 19% over the past ten years .